Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
841 to 860 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries. | Cell Discov | 2021 | 34315862 | PubTator, text mining | PubMed |
| The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. | Blood | 2021 | 34314481 | PubTator, text mining | PubMed |
| Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. | J Clin Oncol | 2021 | 34310172 | PubTator, text mining | PubMed |
| Alternative strategies for optimizing treatment of chronic lymphocytic leukemia with complex clonal architecture. | Leuk Res | 2021 | 34304129 | PubTator, text mining | PubMed |
| Proteomics and Drug Repurposing in CLL towards Precision Medicine. | Cancers (Basel) | 2021 | 34298607 | PubTator, text mining | PubMed |
| Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma. | Br J Haematol | 2021 | 34291829 | PubTator, text mining | PubMed |
| Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors. | Curr Oncol | 2021 | 34287267 | PubTator, text mining | PubMed |
| BCR activated CLL B cells use both CR3 (CD11b/CD18) and CR4 (CD11c/CD18) for adhesion while CR4 has a dominant role in migration towards SDF-1. | PLoS One | 2021 | 34283878 | PubTator, text mining | PubMed |
| 3D-STED Super-Resolution Microscopy Reveals Distinct Nanoscale Organization of the Hematopoietic Cell-Specific Lyn Substrate-1 (HS1) in Normal and Leukemic B Cells. | Front Cell Dev Biol | 2021 | 34277604 | PubTator, text mining | PubMed |
| Prognostic and Therapeutic Value of Apolipoprotein A and a New Risk Scoring System Based on Apolipoprotein A and Adenosine Deaminase in Chronic Lymphocytic Leukemia. | Front Oncol | 2021 | 34277446 | PubTator, text mining | PubMed |
| Ibrutinib-Associated Cardiovascular Events in a Patient Wearing an Implanted Loop Recorder. | Mediterr J Hematol Infect Dis | 2021 | 34276913 | PubTator, text mining | PubMed |
| BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects. | Front Immunol | 2021 | 34276674 | PubTator, text mining | PubMed |
| Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves. | Clin Lymphoma Myeloma Leuk | 2021 | 34274291 | PubTator, text mining | PubMed |
| Low prevalence and independent prognostic role of del(11q) in Chinese patients with chronic lymphocytic leukemia. | Transl Oncol | 2021 | 34273750 | PubTator, text mining | PubMed |
| Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells. | J Immunother Cancer | 2021 | 34272306 | PubTator, text mining | PubMed |
| Identification of Clinically Relevant Subgroups of Chronic Lymphocytic Leukemia Through Discovery of Abnormal Molecular Pathways. | Front Genet | 2021 | 34262590 | PubTator, text mining | PubMed |
| Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia, Focusing on Long Term Cytopenias Before and After the Era of Targeted Therapies. | Pathol Oncol Res | 2021 | 34257611 | PubTator, text mining | PubMed |
| Progress in molecular feature of smoldering mantle cell lymphoma. | Exp Hematol Oncol | 2021 | 34256839 | PubTator, text mining | PubMed |
| [Prognostic value of activated partial thromboplastin time and D-dimer in chronic lymphocytic leukemia]. | Zhonghua Xue Ye Xue Za Zhi | 2021 | 34218587 | PubTator, text mining | PubMed |
| Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. | Cancers (Basel) | 2021 | 34209515 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=43